Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice

Epilepsia

Volumn 54, Issue 7, 2013, Pages 1167-1175

  Shandra, Alexey ^a   Shandra, Pavel ^b   Kaschenko, Olga ^a   Matagne, Alain ^c   Stöhr, Thomas ^c  

^a ODESSA NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b ODESSA NATIONAL UNIVERSITY   (Ukraine)

^c UCB PHARMA   (Belgium)

Author keywords

Motor impairment; Pharmacodynamic drug interactions; Pharmacokinetic drug interactions

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; ROTAROD TEST; SEIZURE;

MOTOR IMPAIRMENT; PHARMACODYNAMIC DRUG INTERACTIONS; PHARMACOKINETIC DRUG INTERACTIONS;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION; MALE; MICE; MICE, INBRED CBA; MOTOR ACTIVITY; ROTAROD PERFORMANCE TEST; SEIZURES;

EID: 84879797069     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12237     Document Type: Article

References (53)

1. Anderson GD,. (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32: 554-563.
2. Barton ME, Klein BD, Wolf HH, White HS,. (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47: 217-227.
3. Ben-Menachem E,. (2008) Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 44: 35-40.
4. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD,. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308-1317.
5. Berenbaum MC,. (1989) What is synergy? Pharmacol Rev 41: 93-141.
6. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T,. (2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13: 21-42.
7. Borowicz KK, Kleinrok Z, Czuczwar SJ,. (2000) The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam. Naunyn Schmiedebergs Arch Pharmacol 361: 629-635.
8. Borowicz KK, Swiader M, Luszczki J, Czuczwar SJ,. (2002) Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 43: 956-963.
9. Brandt C, Heile A, Potschka H, Stoehr T, Loscher W,. (2006) Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47: 1803-1809.
10. Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojärvi J, Doty P,. (2010) Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 24: 1041-1054.
11. Conley JD, Kohn H,. (1987) Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy. J Med Chem 30: 567-574.
12. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM,. (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41: 1364-1374.
13. Doty P, Rudd GD, Stoehr T, Thomas D,. (2007) Lacosamide. Neurotherapeutics 4: 145-148.
14. Duncan GE, Kohn H,. (2005) The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 67: 81-87.
15. Dunham NW, Miya TS,. (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Pharm Assoc 46: 208-209.
16. Errington AC, Coyne L, Stohr T, Selve N, Lees G,. (2006) Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50: 1016-1029.
17. Errington AC, Stöhr T, Heers C, Lees G,. (2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73: 157-169.
18. FDA. (May 2001) Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Silver Spring, MD.
19. Genton P, Roger J,. (1997) Antiepileptic drug monotherapy versus polytherapy: a historical prospective. Epilepsia 38 (Suppl. 5): S2-S5.
20. Gordon R, Gels M, Wichmann J, Diamantis W, Sofia RD,. (1993) Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia 34: 367-371.
21. Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E,. (1992) Ucb L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol 222: 193-203.
22. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, Sullivan T,. SP755 Study Group. (2009) Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 50: 443-453.
23. Hovinga CA,. (2003) SPM-927 (Schwarz Pharma). IDrugs 6: 479-485.
24. Jonker DM, Voskuyl RA, Danhof M,. (2007) Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 48: 412-434.
25. Klitgaard H, Matagne A, Gobert J, Wülfert E,. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353: 191-206.
26. Kohn H, Sawhney KN, LeGall P, Conley JD, Robertson DW, Leander JD,. (1990) Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids. J Med Chem 33: 919-926.
27. Kohn H, Sawhney KN, LeGall P, Robertson DW, Leander JD,. (1991) Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids. J Med Chem 34: 2444-2452.
28. Kwan P, Brodie MJ,. (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319.
29. Lacosamide: Summary of Product Characteristics. (2008) www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/ 000863/WC500050338.pdf
30. Litchfield JT, Wilcoxon F,. (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-113.
31. Loewe S,. (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285-290.
32. Loewe S,. (1957) Antagonism and antagonists. Pharmacol Rep 9: 237-242.
33. Löscher W, Hönack D,. (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232: 147-158.
34. Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, Czuczwar SJ,. (2003) Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44: 1003-1013.
35. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Ratnaraj N, Patsalos PN, Czuczwar SJ,. (2006) Pharmacodynamic and pharmacokinetic characterization of interactions between Levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographical analysis. Epilepsia 47: 10-20.
36. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B,. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101: 9861-9866.
37. Niespodziany I, Leclère N, Foerch P, Wolff C,. (2012) Comparative study of lacosamide and classic sodium channel blocking antiepileptic drugs on sodium channel slow inactivation. J Neurosci Res 9: 436-443.
38. Patsalos PN,. (2004) Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Reviews in Contemporary Pharmacotherapy 13: 1-168.
39. Perucca E,. (1995) Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 162: 31-34.
40. Porreca F, Jiang Q, Tallarida RJ,. (1990) Modulation of morphine antinociception by peripheral [Leu5] enkephalin: a synergistic interaction. Eur J Pharmacol 179: 463-468.
41. Saké JK, Hebert D, Isojärvi J, Doty P, De Backer M, Davies K, Eggert-Formella A, Zackheim J,. (2010) A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 24: 1055-1068.
42. Shah VP, Midha KK, Findley JWA, Hill HM, Hulse JD, McGilverey LJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A,. (2000) Bionalytical method validation-a revisit with a decade of progress. Pharm Res 17: 1551-1557.
43. Sheets PL, Heers C, Stoehr T, Cummins TR,. (2008) Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther 326: 89-99.
44. Stafstrom CE,. (2010) Mechanism of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 23: 157-163.
45. Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS,. (2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74: 147-154.
46. Tallarida RJ,. (1992) Statistical analysis of drug combinations for synergism. Pain 49: 93-97.
47. Tallarida RJ,. (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872.
48. Tallarida RJ,. (2002) The interaction index: a measure of drug synergism. Pain 98: 163-168.
49. Tallarida RJ, Murray RB,. (1987) Manual of pharmacologic calculations with computer programs. 2nd ed. Springer-Verlag, New York, NY.
50. Tallarida RJ, Stone DJ Jr, Raffa RB,. (1997) Efficient designs for studying synergistic drug combinations. Life Sci 61: PL 417-425.
51. Viswanthan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R,. (2007) Quantitative bioanalytical methods validation and implementation: best practices. Pharm Res 24: 1962-1973.
52. Wallin RF, Blackburn WH, Napoli MD,. (1970) Pharmacologic interactions of albutoin with other anticonvulsant drugs. J Pharmacol Exp Ther 174: 276-282.
53. Wasterlain CG, Stöhr T, Matagne A,. (2011) The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res 94: 10-17.